BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,067 filers reported holding BAXTER INTL INC in Q2 2018. The put-call ratio across all filers is 0.99 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $17,184,000 | +227.4% | 205,500 | +242.5% | 1.51% | +68.8% |
| Q3 2019 | $5,248,000 | +70.9% | 60,000 | +60.0% | 0.90% | +92.3% |
| Q2 2019 | $3,071,000 | -46.0% | 37,500 | -46.4% | 0.47% | -42.4% |
| Q1 2019 | $5,692,000 | +35.1% | 70,000 | +9.4% | 0.81% | -3.8% |
| Q4 2018 | $4,212,000 | -8.9% | 64,000 | +6.7% | 0.84% | -13.6% |
| Q3 2018 | $4,625,000 | +56.6% | 60,000 | +50.0% | 0.97% | -17.8% |
| Q2 2018 | $2,954,000 | -39.4% | 40,000 | -46.7% | 1.18% | -58.9% |
| Q1 2018 | $4,878,000 | +7.8% | 75,000 | +7.1% | 2.88% | +52.2% |
| Q4 2017 | $4,525,000 | -73.3% | 70,000 | -74.1% | 1.89% | -61.8% |
| Q3 2017 | $16,942,000 | +123.9% | 270,000 | +116.0% | 4.96% | +65.0% |
| Q2 2017 | $7,568,000 | -18.9% | 125,000 | -30.6% | 3.00% | +8.8% |
| Q1 2017 | $9,335,000 | +40.4% | 180,000 | +20.0% | 2.76% | +13.2% |
| Q4 2016 | $6,651,000 | -12.7% | 150,000 | -6.2% | 2.44% | +5.4% |
| Q3 2016 | $7,616,000 | +14.3% | 160,000 | +8.6% | 2.31% | -18.3% |
| Q2 2016 | $6,661,000 | +4.6% | 147,305 | -5.0% | 2.83% | -2.2% |
| Q1 2016 | $6,367,000 | -44.4% | 155,000 | -48.3% | 2.90% | -40.1% |
| Q4 2015 | $11,445,000 | -57.7% | 300,000 | -24.1% | 4.83% | -65.4% |
| Q1 2015 | $27,058,000 | +427.4% | 395,000 | +464.3% | 13.96% | +639.9% |
| Q4 2014 | $5,130,000 | – | 70,000 | – | 1.89% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |